Harmen Beurmanjer

169 Supplements Population description and results Demographics: 69% male; M=28.8, SD=7.2 years; primary (13.8%), secondary (75.5%), and tertiary (10.6%); education; full-time (22,3%), part-time (11,2%), unemployed (29,8%) unfit for work (29,8%), student (6,4%); single (34.9%), with partner and/or children (24.7%), with parents (26.5%), other (14.0%). Other: 16% re-admissions; nearly a quarter of the admission was not regular: 13% crisis and 10% urgent. GHB use: First use M=25.0, SD=7.4 years. Years of use M=4.2, SD=3.3. Use past 30 days M=29.7, SD=1.4. Relapse within 3 months after detoxification was 64.6%. Estimated GHB dose per intake M=3.88, SD=2.1 g. Estimated daily GHB dose M=56.0, SD=40.3 g. Other substance use: Co-use past 30 days (mean, SD): alcohol (13.1±11.6); cannabis (17.0±12.1); opiates (13.7±11.6); cocaine (9.1±10.7); stimulants (14.8±12.2); sedatives (21.5±11.2); other (26.2±8.3). Use of other substances: alcohol (51%), sedatives (42%), cannabis (41%), amphetamines (41%) and/or cocaine (31%). Other: In 79% psychiatric comorbidity was detected, including anxiety (current 38%, lifetime 40%), mood (13%, 31%), and psychotic disorders (13%, 21%). Demographics: 89% male; M=34, SD=7.2, range 18-45 years; 56% fulltime/student, 37% unemployed, off sick (4%), retired (4%); 56% rented/ owned accommodation, 22% local authority housing, 19% with family/friends, 4% hostel accommodation. Other: 78% gay, 19% heterosexual, 4% bisexual; 89% reported anxiety symptoms (above cut-off ); history of treatment for anxiety (52%); diagnose HIV-positive (37%). GHB use: M=53, SD=46.1, range 5-200, median=40 ml per day. GBL use of M=53 ml/day. First use M=29, SD=8.7, range 18-45 years. Duration of use before first admission M=15, SD=10.0, median=12 months (range 2 months to 3 years). Frequency of use: hourly (41%), 2 hourly (44%), 3 hourly (7%), < daily 2 times (7%); 81% was physically dependent. Recreative use was reported by 56% (clubs, party scene), 22% for psychological reasons, and 19% in a sexual context. Other substance use: 89% concurrent use, most reported: mephedrone 48% (13), ketamine 37% (10), alcohol 33% (9), benzodiazepines 19% (5), cocaine 15% (4), MDMA 11% (3). Demographics: 71.1% male, M=29.3 years, M=11.8 years of education, 30% had work, M=7.174 dollar income (patients >17 years), 4.4% married, 8.9% homeless. Other: 31.1% received medication for psychiatric or addiction problems. DSM-diagnose: Bi-polar (5.3%), depressive disorder (13.2%), no DSM-IV diagnose axis I/II (71.1%). GHB use: First use M=20.5 years. Days of use before admission M=17.4. Abstinent in last month of treatment: 37.2%. Other substance use: primary substance was in 26% club drugs; cannabis (11%), alcohol (6%), methamphetamine (26%), cocaine (7%), crack cocaine (12%), heroine (4%). Demographics: 67% male; median=25, range 21-30 years. Median age of the other patients was significantly higher with 35 years (p<0.001). GHB use: Primary reason in 0.9% of all patients with first treatment episode. Other substance use: 68%. Other: Number of treatment contacts: M=50.4, SE=3.62, median=20, range 7-51. Treatment duration: M=325.2, SE=13.52, median=229, range 90-430 days. Re-admission in 42.8%. All significantly higher than patients in treatment for other substances.